The Successor-1 Study for relapsed or refractory multiple myeloma (RRMM)
- kati810
- Mar 5
- 2 min read
Updated: May 20
All4Cure is providing information about clinical trial for relapsed multiple myeloma called Successor-1 Study
The purpose of this study is to compare the efficacy and safety of an investigational drug called mezigdomide (CC-92480) with FDA-approved drugs bortezomib and dexamethasone (MeziVd) versus an FDA-approved regimen of pomalidomide, bortezomib, and dexamethasone (PVd). This open-label trial is recruiting patients with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide (Revlimid) exposure
If eligible, you may receive:
Study-related medical care
Study-related lab work and procedures
You will not be charged for the study drug, and you may also be eligible for reimbursement of some costs, such as travel or transportation, depending on your location.
Eligible participants must:
Be 18 years of age or older
Have an RRMM diagnosis
Have received 1 to 3 prior lines of antimyeloma therapy
Have documented disease progression during or after their last antimyeloma treatment regimen
Other eligibility criteria may apply
Study participation
The length of participation in the Successor-1 Study will vary for each participant. Approximately 810 participants will be enrolled in the study and will be assigned at random to receive either a combination therapy including mezigdomide or the traditional combination therapy.
The Successor-1 Study consists of:
Screening period: The study doctor will perform tests to determine if an individual is eligible to enroll in the study. This period may last up to 28 days.
Study treatment period: Study participants will be assigned at random to receive either the study drug – mezigdomide – or pomalidomide, a traditional RRMM therapy, in combination with bortezomib and dexamethasone in cycles lasting 21 days. This includes 4 study site visits per cycle for Cycles 1–8 and 2 study site visits for all cycles after Cycle 9.
Post–study treatment follow-up period: Four weeks after stopping the study treatment, participants will be required to return for an end-of-study treatment visit. If study treatment is ended early, participants will be required to return to the study site for a health evaluation.
Long-term follow-up: Study participants will have study site visits every 4 months for up to 5 years. These visits can be done through telemedicine.
Please view the PDF attached for more information.
If you want to learn more, please get in touch with All4Cure at trial@all4cure.com.
Please note: All4Cure has a commercial relationship with Celgene, a Bristol Myers Squibbcompany, the manufacturer of mezigdomide.